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Abstract: The RND family efflux pump AcrAB-TolC in E. coli and its homologs in other Gram-
negative bacteria are major players in conferring multidrug resistance to the cells. While the structure
of the pump complex has been elucidated with ever-increasing resolution through crystallography
and Cryo-EM efforts, the dynamic assembly process remains poorly understood. Here, we tested
the effect of overexpressing functionally defective pump components in wild type E. coli cells to
probe the pump assembly process. Incorporation of a defective component is expected to reduce
the efflux efficiency of the complex, leading to the so called “dominant negative” effect. Being one
of the most intensively studied bacterial multidrug efflux pumps, many AcrA and AcrB mutations
have been reported that disrupt efflux through different mechanisms. We examined five groups of
AcrB and AcrA mutants, defective in different aspects of assembly and substrate efflux. We found
that none of them demonstrated the expected dominant negative effect, even when expressed at
concentrations many folds higher than their genomic counterpart. The assembly of the AcrAB-TolC
complex appears to have a proof-read mechanism that effectively eliminated the formation of futile
pump complex.
Keywords: RND pump; dominant negative effect; assembly; protein-protein interaction; mutation
1. Introduction
Antimicrobial resistance, especially multidrug resistance in bacterial pathogens, is
among the top 10 global threats to humanity [1]. Among the large array of different defense
mechanisms adapted by bacteria, the overexpression of efflux pumps has a significant role
in conferring multidrug resistance. AcrAB-TolC is one of the most extensively studied
efflux pump systems in Gram-negative bacteria, playing a crucial role in the multidrug re-
sistance in bacteria such as Eshcherichia coli [2–4]. AcrAB-TolC is a member of the resistance
nodulation division (RND) superfamily. AcrAB-TolC efflux pump confers resistance to a
broad spectrum of antimicrobial compounds including β-lactams, tetracycline, novobiocin,
and fluroquinolones [5,6]. This tripartite efflux transporter consists of three major protein
components [7,8], an outer membrane channel TolC, a periplasmic adaptor protein (PAP)
AcrA, and an inner membrane proton-driven antiporter AcrB [9–12]. TolC forms a channel
that spans the outer membrane and acts as the exit pathway of substrates translocated
from the inner membrane and the periplasmic space. AcrA has function in stabilizing
the connection between the two membrane components TolC and AcrB [13,14]. The RND
transporter protein AcrB is responsible for substrate recognition and energy transduction.
Upon binding of a substrate, AcrB uses the energy from the proton flow down its concen-
tration gradient through a proton translocation pathway in the transmembrane domain to
drive the conformational change necessary to move the substrate upward toward the exit
tunnel [4,15]. TolC is shared by several efflux systems, hence E. coli strains deficient in TolC
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are more sensitive to a wider variety of chemicals (e. g. detergents, drugs, bile salts, and
organic solvents) [16,17].
With the dedication of many research groups, the structure and mechanism of drug
efflux by the RND pumps have been brought to light. The first crystal structure of the
pump component was determined for TolC by Koronakis et al. [18] in 2000. TolC is a
trimer with an overall length of 140 Å with 40 Å in the β-barrel domain mainly composed
of β strands, and 100 Å in the periplasmic domain mainly composed of α-helices. The
periplasmic end of the TolC tunnel is sealed at the resting state, which likely opens by
an allosteric protein–protein interaction mechanism [19]. In 2002, Murakami et al. first
reported the crystal structure of AcrB, followed by the proposal of the functional rotation
mechanism [20–22]. Later in 2006, Mikolosko and coworkers determined the crystal
structure of AcrA. In contrast to the trimeric TolC and AcrB, AcrA forms a hexamer in
the pump assembly [23]. The assembled pump structure was first proposed as the “deep
interpenetration model”, which shows that AcrB and TolC have direct interactions with
AcrA wrapped around on the outside to strengthen the interaction [24]. More recently,
Wang et al. proposed a new model based on Cryo-EM studies, known as the “tip-to-tip
model”. In this model, AcrA hairpins form a barrel-like conformation, contacting TolC in
a tip-to-tip arrangement [25,26]. The recent determination of the complex structure first
by cryo-EM, then by X-ray crystallography, confirmed the tip-to-tip model [7,19,20,27–30].
Energy does not seem to be required to assemble the AcrAB-TolC complex and AcrAB
could interact with the TolC channel to form a AcrAB-TolC complex even in the absence of
known substrate [31]. The dynamic process that leads to the formation of the complex is
still elusive.
The dominant negative effect describes the phenomena in which an excess of a func-
tionless mutant of a protein in the presence of its wild type counterpart, reduces the
observed activity due to competition from the mutant for interaction with functional part-
ners of the protein of interest. In the AcrAB-TolC complex, over-expression of functionless
AcrB or AcrA mutant in wild type E. coli strains is expected to drastically reduce the
assembly of functional efflux complex, and thus reduce the efflux activity and increase
the sensitivity to substrate compounds. However, we tested the overexpression of several
functionally defective mutants in the wild type E. coli strain, but did not observe the ex-
pected level of reduction. We speculate that the assembly of the AcrAB-TolC is a precisely
controlled process involving delicate proof-reading procedures.
2. Results
2.1. AcrB Mutants Defective in Proton Transport
Several key residues have been identified in the AcrB transmembrane domain, forming
the proton translocation pathway [20,30,32–38]. We have created single alanine replacement
mutations at each of these sites to obtain mutants AcrB-D407A, AcrB-D408A, AcrB-K940A,
AcrB-T978A, and AcrB-R971A [34,37]. The plasmid encoding of these mutants was first
transformed into the BW25113∆acrB strain to examine their efflux activity (Table 1). As
expected, the minimum inhibitory concentrations (MICs) of most examined substrates
against the strains containing the mutants were the same as those against the strains
without plasmids. The only mutant that displayed significant activity is T978A, which
remained partially active. As a positive control, we showed that transformation with a
plasmid encoding the wild type AcrB completely restored the efflux activity with MIC
values similar to a wild type BW25113 strain. Next, we transformed these plasmids into
the wild-type BW25113 strain and measured the MIC. We expected the AcrB mutants to
compete with the genomic AcrB in binding and interaction with genomic AcrA and/or
TolC, thus reduce the number of functional efflux complexes and subsequently the drug
susceptibility. However, we observed a two-fold reduction of MIC value in some cases,
and no reduction in others, which is consistent with an earlier study reporting the modest
reduction of substrate susceptibility when AcrB-D407A was over-expressed in a wild -type
E. coli strain (Table 1) [39].
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Table 1. MIC values (µg/mL) of BW25113 or BW25113∆acrB strains containing the indicated plasmid encoding AcrB
mutants defective in proton translocation pathway.
Substrate 1 NOV ERY TPP EtBr R6G NA
BW25113∆acrB
containing
/ 4 4 4 8 8 1
WT 128 64 256 128 256 4
D407A 4 4 4 8 8 ND
D408A 4 4 4 8 8 ND
K940A 8 4 4 8 8 ND
R971A 8 4 4 8 16 ND
T978A 8 8 16 32 128 ND
BW25113
containing
/ 256 64 1024 512 1024 4
WT 512 128 1024 512 1024 4
D407A 128 64 1024 256 512 4
D408A 128 64 1024 512 1024 4
K940A 256 64 1024 512 1024 4
R971A 128 32 1024 512 1024 4
T978A 256 64 1024 512 1024 2
1 NOV, novobiocin. ERY erythromycin, TPP tetraphenylphosphonium, EtBr ethidium bromide. R6G, rhodamine 6G, NA, nalidixic acid.
ND, not determined.
We conducted the MIC assay under the basal expression condition without induction
to avoid the potential artifact that may arise from over-expression. To examine how
much of each mutant actually expressed under the basal condition, we prepared samples
from BW25113 containing different plasmids, and compared the expression level from the
plasmid to the level of genomic AcrB. Even without induction, under our experimental
condition, the plasmid-encoded mutants were expressed at a much higher level (5–20 folds
higher) compared to the level of the genomic AcrB (Figure 1a). This result indicates that the
lack of impact on drug susceptibility is not due to the lack of expression. Even presented at
a large excess, the mutants were not effective in disrupting the normal efflux activity.
Single mutations on the proton relay pathway do not significantly affect the overall
structure of AcrB. The crystal structure of a couple of these mutants have been determined
using X-ray crystallography [34,40]. All mutants form trimeric structures similar to those in the
wild-type AcrB [34]. To examine if a mutant defective in proton translocation could still bind
AcrA, we used two inter-subunit disulfide bonds as our yardsticks to probe the interaction
between AcrA and AcrB. We first constructed a plasmid expressing both AcrA and AcrB
(pBAD33-AcrAB), then introduced a pair of cysteines, one in AcrA and the other in AcrB: AcrA-
P57C/AcrB-N191C, and AcrA-T217C/AcrB-S258C. These residues are predicted to be close to
each other according to the “Disulfide by Design 2.0” (http://cptweb.cpt.wayne.edu/DbD2/
(accessed on 6 January 2019)) [41]. The formation of disulfide bond linked AcrA-AcrB complex
was confirmed using anti-AcrA and anti-AcrB Western blot (Figure 1b). A high molecular
weight complex could be detected in both blots, which disappeared upon incubation with β-
mercaptoethanol (BME). The disulfide bond-linked species migrated slightly differently in the
gel, likely due to differences in the conformations of the two complexes under the gel running
condition. Mutation and disulfide bond formation did not significantly impair efflux activity,
as revealed in the MIC measurement (Table 2). Next, we introduced the D408A mutation into
both constructs to examine the effect of this additional mutation on the formation of disulfide
bond linked AcrA-AcrB complex. If the D408A mutation had a significant impact on the
interaction between AcrB and AcrA, we expect to see a reduction of the intensity of the high
molecular weight AcrA-AcrB complex. As shown in Figure 1c, disulfide bond formation was
to a similar level in both constructs, suggesting that the additional D408A mutation did not
have a significant impact on AcrA-AcrB interaction.
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Figure 1. Characterization of mutants defective in the proton translocation pathway. (a) The point
mutation did not affect expression level. Anti-AcrB Western blot analysis of the expression of all
five mutants and the wild-type AcrB from plasmid transformed into BW25113. Sample prepared
from plasmid-free BW25113 (\) was lso prepared and loade to serve as control to highlight the
differ nce in expression lev ls. (b) Anti-AcrB and Anti-AcrA West rn blot an lyses rev aling the
formation of disulfide bonded AcrA-AcrB complexes, which was reduced after incubation with BME.
AcrA-P57C/AcrB-N191C (lane 1 and 3), AcrA-T217C/AcrB-S258C (lane 2 and 4). (c) Similar to b,
with the additional D408A mutation introduced into the constructs. AcrA-P57C/AcrB-N191C/AcrB-
D408A (lane 1 and 3), AcrA-T217C/AcrB-S258C/AcrB-D408A (lane 2 and 4). Molecular weight
markers are labeled as “M” and the molecular weight of bands (kD) were indicated on the right. The
expected bands for AcrA, AcrB, and disulfide bond linked AcrA-AcrB are marked on the left of the
gels s A, B, and AB, respectively. (d) Anti-AcrB (left) and anti-AcrA (right) Western blot analysis of
BW25113 expressing plasmid pBAD33-AcrAB (WT) or pBAD33-AcrAB-D408A (D408A). Samples
prepared from BW25113 not containing plasmid was used as the control (/). For anti-AcrA Western
blot, plasmid-containing samples were diluted 4-fold before being loaded into the gel.
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Table 2. MIC values (µg/mL) of BW25113 and BW25113∆acrAB strains containing the indicated plasmid encoding gene for
both AcrA and AcrB.
Substrate NOV ERY TPP EtBr R6G
BW25113∆acrAB containing
/ 4 4 8 4 16
WT 32 32 128 128 32
AcrA/AcrB-D408A 4 2 8 8 8
AcrAP57C/AcrBN191C 32 16 64 64 32
AcrA-T217C/AcrB-S258C 64 16 128 128 32
BW25113 containing
/ 256 32 1024 512 512
AcrAB-WT 256 64 1024 512 1024
AcrAB-D408A 256 32 1024 512 512
To examine if the additional expression of AcrA from the same plasmid as the AcrB-
D408A have any impact on the competition with the genomic AcrB, we introduced plasmid
pBAD33-AcrAB-D408A into the wild type BW25113 strain and examined the MIC. Both
AcrA and AcrB-D408A expressed at levels much higher than their genomic counterparts
(Figure 1d), and yet, no dominant negative effect was observed (Table 2).
2.2. AcrB Mutants Defective in Substrate Binding
One feature of the AcrAB-TolC complex that has drawn much research interest is their
ability to efflux a large array of substrates ranging broadly in molecular weight, charge,
and hydrophobicity. Many mutations have been introduced in the substrate binding pocket
in AcrB to probe their impact on the efflux of different substrates [30,42]. We chose three
such mutants to include in this study, F610A, I278A, and F178A, since they were reported
to have the most significant impact on efflux. First, plasmids containing single residue
mutations at these sites were introduced into BW25113∆acrB to examine their activities
(Table 3). While the F610A mutant is largely inactive, both F178A and I278A remained
partially active, which is consistent with previous reports [43]. It is clear that in general,
single point mutations introduced at the substrate binding site are not as detrimental
as mutations introduced in the proton translocation pathway. This is reasonable when
considering several residues collectively form a substrate binding site, while the proton
translocation pathway is more linear.
Table 3. MIC values (µg/mL) of BW25113 and BW25113∆acrB strains containing the indicated plasmid encoding AcrB
mutants defective in substrate binding.
Substrate NOV ERY TPP EtBr R6G NA
BW25113∆acrB containing
/ 4 4 4 8 8 1
WT 128 64 256 128 256 4
F610A 8 8 64 32 128 ND
F178A 64 8 128 128 256 ND
I278A 32 32 128 128 128 ND
BW25113 containing
/ 256 64 1024 512 1024 4
WT 512 128 1024 512 1024 4
F610A 512 64 1024 512 1024 2
F178A 512 64 1024 512 1024 4
I278A 512 64 1024 512 1024 4
Next, plasmids encoding these mutations were transformed into BW25113 to deter-
mine their impact on efflux activity. Similar to proton relay pathway mutants, the MIC
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values of the strain were not significantly affected (Table 3). The presence of AcrB mutants
defective in substrate binding does not display the dominant negative phenotype either.
Next, we examined the expression of these mutants under the basal condition (Figure 2a).
Similar as described above, the plasmid-encoded mutants were expressed at a much higher
level compared to the level of the genomic AcrB, indicating that the lack of impact on MIC is
not due to the lack of expression.
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teraction with TolC [44]. We created three such mutants, R128D, L132D, and S139D, and 
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Figure 2. Characterization of AcrB mutants defective in substrate binding. (a) The point mutation did
not affect expression level. Anti- Western blot analysis of as l xpression of all three mutants
and the wild type AcrB from plasmid transformed into BW25113. Sample prepared from plasmid-
free BW25113 (\) was also prepared and loaded to serve as a control to highlight the difference
in expression levels. (b) Anti-AcrB and Anti-AcrA Western blot analyses revealing the formation
of disulfide bonded AcrA-AcrB complexes, which was reduced after incubation with BME. AcrA-
P57C/AcrB-N191C, F610A is in lane 1 and 3, and AcrA-T217C/AcrB-S258C, F610A in lane 2 and 4.
Molecular weight markers are labeled as “M” and the molecular weight of bands (kD) were indicated
on the right. The expected bands for AcrA, AcrB, and disulfide bond linked AcrA-AcrB are marked
on the left of the gels as A, B, and AB respectively.
To determine if a mutation in the substrate binding pocket of AcrB (F610A) affects
interaction between AcrB and AcrA, we used the disulfide bond pairs as described above
and introduced an additional AcrB F610A mutation (Figure 2b). Similar as in Figure 1b,
AcrA-AcrB complexes were observed, similar as in samples without the F610A mutation,
suggesting that the AcrB F610A mutant still binds with AcrA.
2.3. AcrA Mutant Defective in TolC Interaction
AcrA is the periplasmic adaptor protein of the efflux system. While debate still exists
concerning the conformation of AcrA in the final assembled pump, it was clear that several
residues at the tip of its long α-helical hairpin loop play an important role in the interaction
with TolC [44]. We created three such mutants, R128D, L132D, and S139D, and introduced
plasmids encoding these mutants first into BW25113∆acrA to confirm that they are not
active (Table 4). As expected, the mutants were largely inactive. The plasmids were
then transformed into BW25113 and substrate susceptibility of the strains were measured.
Similar to the AcrB mutants, we did not observe the dominant negative effect.
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Table 4. MIC values (µg/mL) of BW25113 and BW25113∆acrA strains containing the indicated
plasmid encoding AcrA mutants.
Substrate NOV ERY TPP R6G NA
BW25113∆acrA containing
/ 4–8 2 4 4 1
WT 64 32 256 128 4
L132D 8 2 4 4 ND
R128D 4 2 4 4 ND
S139D 4 2 8–16 4 ND
A113D 64 4 32 16 ND
A155D 8 4 8 4 ND
A113D, A155D 8 2 8 4 ND
L50C 32 8 32 32 ND
I52C 32 4 16 32 ND
E229C 32 4 32 16 ND
R225C 16 8 64 16 ND
L50C, R225C 4 8 8 4 ND
I52C, R225C 4 4 8 8 ND
I52C, E229C 4 2 4 4 ND
BW25113 containing
/ 512 64 1024 512 4
R128D 512 64 1024 512 4
L132D 512 64 1024 512 4
S139D 256 64 1024 512 4
A113D 512 64 1024 512 4
A155D 512 64 1024 512 4
A113D, A155D 512 64 1024 512 4
L50C 512 64 1024 512 4
I52C 256 64 1024 512 4
E229C 512 64 1024 256 4
R225C 512 64 1024 512 4
L50C, R225C 512 64 1024 256 4
I52C, R225C 512 128 1024 512 4
I52C, E229C 512 128 1024 512 4
Next, we examined the expression of AcrA from the plasmids. As discussed above for
AcrB mutants, we did not induce expression. Both the MIC study and the expression level
detection experiments were performed under the basal expression condition. Expressions
of the mutants (R128D, L132D, S139D) were higher than the expression level of the genomic
AcrA (Figure 3a). To make the sample intensity comparable on the Western blot analysis,
samples prepared from plasmid-containing strains were diluted 4-fold before being loaded
into the gel. Thus, the expression levels of the mutant AcrA constructs were 10–20 folds
higher than the expression level of the wild type AcrA from the genome. While these
mutants had been studied for their impact on interaction with TolC, it was not clear if
they would have an impact on binding with AcrB. We used the double Cys mutants as
described above to probe the interaction between AcrA-R128D and AcrB (Figure 3b). This
extra mutation did not seem to disrupt the interaction between AcrA and AcrB.
Antibiotics 2021, 10, 830 8 of 17
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Figure 3. Characterizatio of Acr utants defective in TolC interaction. (a) Anti-AcrA estern
blot analysis of samples prepared from BW25113 containing plasmid expressing the indicated AcrA
mutant (diluted 4- folds). Sample prepared from plasmid-free BW25113 was also prepared and
loaded without dilution (\) to serve as a control to highlight the difference in expression levels.
(b) Anti-AcrB and Anti-AcrA Western blot analyses revealing the formation of disulfide bonded
AcrA-AcrB complexes, which was reduced after incubation with BME. AcrA-P57C/AcrB-N191C,
R128D (lane 1 and 3), AcrA-T217C/AcrB-S258C, R128D (lane 2 and 4). Molecular weight markers are
labeled as “M” and the molecular weight of bands (kD) were indicated on the right. The expected
bands for AcrA, AcrB, and disulfide bond linked AcrA-AcrB are marked on the left of the gels as A,
B, and AB, respectively.
2.4. AcrA Mutant Defective in AcrA Assembly
According to the cryo-EM structure of the complex, AcrA forms a hexameric barrel,
with each subunit contributing a long helical hairpin. We speculate that mutations intro-
duced at neighboring sites between the hairpins would disrupt the interaction between
neighboring AcrA subunits, and thus disrupt the formation of the helical barrel. We chose
two sites to introduce mutation, A113 and A155. They are located at the inter-subunit
interface in the middle of the long hairpin. We created both single and double mutants
containing A113D and A155D. Plasmids encoding these strains were first transformed into
BW25113∆acrA to examine the impact of the mutation on the efflux activity (Table 4). Both
mutations disrupted efflux, as revealed by a reduction of the MIC. The A155D mutation is
more detrimental than A113D. Both A155D and the double mutations A113D/A155D were
largely inactive. When transformed into BW25113, we still did not observe a significant
reduction of MIC. The expression levels of the mutants were examined to confirm that
mutants did express in excess compared to the level of the genomic AcrA under the exper-
imental condition. As shown in Figure 4a, the expression of the mutants was similar or
slightly higher than that of the genomic AcrA. We next used the inter-AcrA/AcrB disulfide
bond pairs to examine the impact of A155D mutation on the interaction between AcrA and
AcrB (data not shown). This additional mutation did not have a significant impact on the
level of disulfide bond formation, indicating that it did not disrupt the interaction between
AcrA and AcrB.
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Figure 4. Anti-AcrA Western blot analysis of samples prepared from BW25113 containing plasmids
expressing the indicated AcrA mutant (diluted 4-folds). Sample prepared from plasmid-free BW25113
was also prepared and loaded without dilution (\) to serve as a control to highlight the difference
in expression levels. (a) AcrA mutants are expected to affect AcrA–AcrA interaction during pump
assembly. (b) AcrA mutants forming intra-subunit disulfide bond to be trapped in an inactive
conformation. Addition of BME did not lead to an observable change in mobility.
2.5. AcrA Mutant Defective in Conformational Change
We created three pairs of defective AcrA mutants that are trapped in a nonfunctional
confirmation via a disulfide bond, L50C-R225C, I52C-R225C, and I52C-E229C [45]. Hazel
et al. fi st created these m tants to examine their hypothesis that AcrA a opts two confor-
mations, a cis-like conformation in which me brane proximal (MP) and α-helical domains
point to the same direction, and a trans-like conformation in which they point to opposite
directions. We created the corresponding single and double mutants and confirmed that
the double mutants were largely inactive when transformed into BW25113∆acrA (Table 4),
consistent with previous report. Yet, expression of these mutants in the BW25113 strain
did not have a significant impact on the efflux of AcrAB-TolC substrates. We have also
examined the expression of the mutants and confirmed that they were present in the cells
a a higher level than the genomic AcrA (Figure 4b).
2.6. AcrA Mutants in a Strain Containing Anchor-Free AcrA
Finally, we examined the potential contribution of the lipid anchoring of AcrA on
the stability of AcrA-AcrB interaction. Toward this goal, we engineered a BW25113 strain
(BW25113spmut) in which the signal peptide of AcrA (residue 1–24 encoded in the acrA
gene) in the genome was replaced with the signal peptide of OmpA. The OmpA signal
peptide directs the secretio of the AcrA to the periplasm after synthesis. The lipid
anchoring was abolished, but the activity of AcrA was not affected [13]. We reaso
that r moval of the lipid anchoring might favor dissociation of AcrA from AcrB in the
AcrA-AcrB complex, and thus providing an opportunity for the mutant AcrA, which
is lipid-anchored, to compete more effectively for binding with AcrB. We transformed
above-mentioned AcrA mutant into BW25113spmut and measured the MIC of the strains
(Table 5). We still did not observe a significant drop in efflux activity.
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Table 5. MIC values (µg/mL) of BW25113spmut strain containing the indicated plasmid encoding
AcrA mutants.
Substrate NOV ERY TPP R6G
/ 512 128 2048 1024
R128D 512 128 2048 1024
L132D 512 128 2048 1024
S139D 512 128 2048 512
A113D 512 128 2048 512
A155D 512 128 2048 512
A113D, A155D 512 128 2048 512
L50C, R225C 512 128 2048 512
I52C, R225C 512 128 2048 1024
I52C, E229C 512 128 2048 1024
2.7. Slow Dissociation of the AcrAB Complex
We speculate that the AcrAB complex, once formed, dissociates very slowly. To
experimentally test this speculation, we introduced a plasmid encoding AcrA bearing
a histag at the C-terminus (AcrA-his) into a wild-type and the corresponding acrA
knockout strains. We first confirmed that under our experimental condition, the
genomic AcrB could not be purified using metal affinity chromatography (Figure 5a).
In the absence of the plasmid, no AcrB could be detected in the eluate in anti-AcrB
Western blot. In contrast, when AcrA-his was introduced into the cells, AcrB could
be detected in the eluates, indicating that it was co-purified through interaction with
AcrA-his. Interestingly, the AcrB band intensity was higher in the eluate prepared from
the acrA knockout strain, indicating more AcrB were co-purified. Next, we examined
the time course of co-purification. The rationale is, in the wild-type strain, genomic
AcrB and AcrA form stable complexes. If the dissociation is fast, the introduced AcrA-
his will quickly compete with genomic AcrA to form a complex with AcrB, and in
turn enable purification of AcrB through metal affinity chromatography. Otherwise, if
the dissociation is slow, then it takes much longer for the competition to happen. We
monitored the formation of AcrAB complex between the genomic AcrB and plasmid-
expressed AcrA-his at three-time points, right after the induction period, and 5 and 17 h
after induction (Figure 5b). We performed crosslinking right before protein extraction
and purification to stabilize the complexes. As a control experiment, we also examined
the formation of the AcrAB complex between the genomic AcrB and plasmid-expressed
AcrA-his in an acrA gene knock-out strain. In this case, we do not expect competition
from the genomic AcrA; thus complex should form faster. We found that the formation
of the complex is plateaued much faster in the acrA knockout strain, as intensities of
the eluates prepared from 5 and 17 h into incubation were very similar. In contrast,
it took much longer for AcrB to interact with AcrA-his in the wild type strain, which
is likely due to the requirement of an extra step of AcrAB dissociation between the
genomic AcrA and AcrB.
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Figure 5. Co-purification of genomic AcrB with AcrA-his. (a) Anti-AcrB Western blot analyses of
samples prepared from BW25113 or BW25113∆acrA with or without plasmid-encoded AcrA-his.
(b) Anti-AcrB Western blot analyses of samples collected after 0, 5, or 17 h of incubation following
the induction of AcrA-his production in BW25113 or BW25113∆acrA strains. Dithiobis-(succinimidyl
proprionate) (DSP) crosslinking was performed to stabilize the AcrAB complex before protein
purification. Reduction using dithiothreitol (DTT) breaks the disulfide bond in the linker of DSP and
the complex into AcrA and AcrB subunits. Molecular weight markers are labeled as “M”, and the
molecular weight of bands (kD) were indicated on the right. The expected bands for AcrB and DSP
linked AcrA-AcrB are marked on the left of the gels as B and AB, respectively.
3. Discussion
The dominant negative effect describes the situation in which the phenotype is domi-
nated by the negative impact of the functionless mutant. The observation of the dominant
negative effect has been used in many studies to investigate the mechanism of protein–
protein interaction, including the identification of protein–protein interactions interface [46],
determination of enzymatic activity related to oligomerization [47], and the effect of muta-
tions in genetic disorders [48,49].
In the process of AcrAB-TolC assembly, there are many steps where the incorporation
of a functionless AcrA or AcrB mutant would negatively impact the efflux activity. First, all
three proteins in the system are oligomers. AcrB and TolC are obligate timers, while AcrA
is believed to exist as a dimer or trimer in the free form and assembles into a hexamer in
the pump complex [13,50]. While AcrA and AcrB are believed to form a complex in the
absence of substrate and efflux, TolC assembles with AcrAB during active efflux. When
a functionless AcrA mutant is expressed in excess in a wild type E. coli cell containing
genomic AcrA, we expect them to compete with their genomic counterpart to engage
genomic AcrB, forming non-functional interactions to reduce the overall efflux activity.
Similarly, we expect functionless AcrB mutant expressed from a plasmid to compete with
genomic AcrB for genomic AcrA. In addition, we expect the competition for genomic
TolC will further enhance the dominant negative effect. For this competition to occur, we
chose mutants that are defective due to mechanisms not directly related to the interaction
between AcrA and AcrB. The structure of the AcrAB-TolC complex and location of mutants
mentioned in this study are shown in Figure 6. We determined the expression level of
the mutants relative to their genomic counterpart. Using serial dilution and quantitative
Antibiotics 2021, 10, 830 12 of 17
Western blot analysis, we found that the expression levels of the AcrB mutants were
10–20 folds of the level of the genomic AcrB, and the AcrA mutants were 2 to 20 folds
of the level of the genomic AcrA. With this high level of excess, we expect to observe
a strong dominant-negative effect if the mutants were actively involved in the pump
assembly, competing for binding partners. We constructed five groups of AcrA and AcrB
mutants, defective in different aspects. We observed that the effect of certain mutations
was not always the same for different substrates. For example, T978A mutation in AcrB
is detrimental to all substrates tested except for R6G, while F178A mutation in AcrB
drastically reduced the MIC for ERY, but not as much for other substrates tested. This
difference in mutation effects has been observed in many studies characterizing AcrA and
AcrB mutants, for example, [23,42,45]. We speculate that this difference could be due to
differences in the binding and interaction of specific substrates with the pump complex.
The substrates vary drastically in their size, shape, structure, and charged state. As a result,
the subgroup of residues that they interact with on their way to be transported are not
likely to completely overlap. Therefore, point mutations introduced in AcrA and AcrB
could have different impacts on specific substrates.
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Figure 6. Structure of the AcrAB-TolC complex with the residues mutated in this study highlighted
in AcrA and AcrB structures. AcrA mutations labeled as; A1-L50C, A2-I52C, A3-P57C, A4-A113D,
A5-L132D, A6-S139D, A7-A155D, A8-T217C, A9-R225C, A10-E229C. AcrB mutations are labelled
as; B1-F178A, B2-I278A, B3-D407A, B4-D408A, B5-F610A, B6-K940A, B7-R971A, B8-T978A. AcrAB
crystal structure is created using pymol from 5N5G.pdb (https://pymol.org/2/ (accessed on 15
Marth 2021)).
Mutants defective in the proton translocation pathway still form trimers [34] and
interact properly with AcrA (Figure 1c). Then, was why no dominant negative effect
observed? One possibility is that the genomic AcrA and AcrB are transcribed together,
sharing the same mRNA. Hence, the newly produced AcrA and AcrB could be clustered
as well. As a result, the genomic AcrA and AcrB form a AcrAB complex as soon as they
are translated and inserted into the membrane (AcrB) or secreted into the periplasm with
lipid anchoring (AcrA). Since the local concentration of the genomic proteins are high, they
associate with each other with a much higher chance than associate with a plasmid-encoded
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partner. Another requirement for the observed activity is that the AcrAB complex, once
formed, should be resistant to dissociation. Otherwise, the high concentration of AcrB
mutant in the cell membrane would be effective in competing with genomic AcrB to form
a nonfunctional AcrAB complex.
We further examined the impact of over-expressing both AcrA and AcrB, in which
the entire sequence coding AcrA and AcrB were inserted in a plasmid. As a result, we
expect them to form AcrA-AcrBD408A complex to compete with plasmid encoded AcrAB
for genomic TolC. Yet, while the expression level of the complex was ~20 fold higher than
that of the genomic AcrAB, no significant reduction of MIC was observed. It appears that
TolC could differentiate the two complexes, even though the only difference between them
is the single residue mutation down in the transmembrane domain of AcrB.
The second group of AcrB mutants examined are defective in substrate binding.
These mutations are not expected to affect AcrB structure [42,51], nor do they impact the
interaction between AcrA and AcrB (Figure 2b). However, we did not observe a significant
reduction of MIC.
We also examined the effect of expressing AcrA mutants on the efflux activity. The
first group of residues we tested are ones that impact AcrA interaction with TolC, as they
are involved in the tip-to-tip interaction with TolC [44]. We confirmed that a representative
mutant in this group, R128D, still binds to AcrB (Figure 3b). Similarly, we expect the
expression of these mutants will lead to competition with genomic AcrA for genomic
AcrB, and the formation of a nonfunctional complex. However, no reduction of MIC was
observed. To further probe the interaction of AcrA and AcrB, we created a strain of E. coli
that is genetically modified to replace the signal peptide of AcrA with the signal peptide
of OmpA (BW25113spmut). The resultant AcrA can still be secreted into the periplasm
and is fully functional, but the lipid anchoring is lacking [13]. With this free-floating AcrA,
we expect the interaction between AcrA and AcrB to be weakened, which may increase
the competitiveness of the plasmid encoded AcrA, which is lipid anchored. Yet, we did
not observe a reduction of MIC when the functionless mutants were expressed in strain
BW25113spmut.
The next group of AcrA mutants contains changes at the inter-subunit interface of
AcrA to disrupt formation of the functional hexametric ring. While the A155D single
mutation was enough to completely abolish activity, expression of the protein in BW25113
did not lead to a reduction of MIC. Finally, we examine a group of AcrA that forms disulfide
bond locked conformation that is functionally incompatible. Again, similar as other groups,
over-expression of these mutants did not have a significant impact on MIC.
In conclusion, we examined the effect of plasmid-encoded AcrA and AcrB mutants in
wild type E. coli cells, to probe the potential disruption of normal AcrA-AcrB-TolC assembly
in the presence of excess mutants of AcrA or AcrB. To our surprise, none of the five groups
of mutants showed the so-called “dominant negative” effect. This observation indicates
that the RND pump assembly process in Gram-negative bacteria is a precisely controlled
process that prevents the formation of functionless complex. An alternate explanation is
the possibility that efflux depends on only a very small population of AcrAB-TolC pumps
active at a given moment, as the population of active AcrAB-TolC pumps was not detectable
in situ in E. coli [19]. If the majority of AcrAB and TolC in the cells are idle, then the effect
of over-expressing functionless mutant would be greatly limited. In addition, our results
suggest that dissociation kinetics of the AcrAB complex is very slow. Once formed, the
complex remains bound and does not dissociate easily.
4. Materials and Methods
4.1. Bacterial Strains, Plasmids, and Growth Conditions
Escherichia coli BW25113 and BW25113∆acrB were obtained from Yale E. coli genetic
resources. BW25113∆acrAB, BW25113∆acrA were constructed using the E. coli gene deletion
kit (Cat #K006, Gene Bridge) following the manufacturer’s protocol. Plasmids pBAD33-
AcrB and pBAD18-AcrA were created in our previous study [52]. To create the plasmid
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pBAD33-AcrAB, acrAB gene was amplified from genomic DNA of BW25113 and cloned
into pBAD33 by following the fast cloning method described previously by Li et al. [53].
Plasmids pBAD33-AcrB, pBAD33-AcrAB, and pBAD18-AcrA were used as the templates
to create respective mutations discussed below. Mutations were introduced using the
Quikchange site-directed mutagenesis kit following manufacturer’s instructions (Agilent,
Santa Clara, CA, USA). BW25113spmut, in which the signal peptide of AcrA was exchanged
with the signal peptide of outer membrane protein OmpA, was created using the CRISPR-
Cas9 system by following the published protocol [54]. Plasmids pTargetF and pCas were a
gift from Shen Yang (Addgene plasmid #62226 and #62225) [54]. Bacteria were cultured at
37 ◦C with shaking at 250 rpm in Luria broth (LB) media unless otherwise noted.
4.2. Drug Susceptibility Assay
The minimum inhibitory concentration (MIC) was determined for erythromycin, novo-
biocin, ethidium bromide (EtBr), rhodamine 6G (R6G), nalidixic acid, and tetraphenylphos-
phonium chloride (TPP) following the CLSI guidelines [55]. Briefly, overnight cultures of
the indicated strain were diluted to a final concentration of 105 CFU/mL in fresh Muller
Hinton Broth 2 (cation adjusted) media (Millipore Sigma, St. Louis, MO, USA) in a 48 well
microtiter plate containing the indicated compounds at two-fold serial dilutions. Plates
were incubated at 37 ◦C with shaking at 160 rpm for 17 h; the absorbance at 600 nm (OD600)
were measured to identify the lowest concentrations with no observable cell growth. All
experiments were repeated at least three times.
4.3. Protein Expression, SDS-PAGE and Western Blot Analysis
For expression test, 5 mL of cells were cultured overnight at 37 ◦C with shaking at
250 rpm. The next morning, the cell was inoculated with a 100-fold dilution into a 5 mL
fresh LB media supplemented with antibiotics and grow until ~OD600 1.0. Cells were
pelleted and resuspended in 1 mL phosphate buffer containing phenylmethylsulphonyl
fluoride (PMSF) (1:1000 dilution of a saturated ethanol solution) and sonicated for 1 min
followed by centrifugation for 10 min at 15,000 rpm. The supernatant was removed, and
cell pellets were resuspended in 0.1 mL PBS containing 2% Triton-X100. The samples
were incubated at room temperature with shaking for 45 min and centrifuged again for
10 min. The supernatant was used for SDS-PAGE and Western blot analysis. For studies
of disulfide bond formation, iodoacetamide (IAM) was added to a final concentration of
20 mM in all buffers. To reduce disulfide bond, β-mercaptoethanol (BME) was added to a
final concentration of 2% followed by incubation at room temperature for 30 min.
For AcrAB dissociation experiment, BW25113 or BW25113∆acrA containing plasmid
pBAD18-AcrA was cultured to the log phage (OD600 0.8) and arabinose was added to a
final concentration of 0.2% (w/v) to induce the expression of AcrA for 50 min. The cells
were then pelleted, washed, and resuspended with fresh LB. An aliquot of cell culture
was collected, pelleted, and stored at −20 ◦C. The rest of the cell culture was returned
to the shaker and cultured for 5 h, and another aliquot of sample was collected, pelleted,
and stored at −20 ◦C. The last sample was collected at 17 h. OD600 of the samples were
measured and used to adjust the sample volume collected to ensure that the same number
of cells were used for each time point. All pellets were resuspended and sonicated to lyse
the cells. After centrifugation, the pellet was extracted using PBS + 2% Triton for 2 h. The
mixtures were centrifuged again and the supernatants were incubated with Ni beads for
40 min, followed by washing with the same buffer supplemented with 50 mM imidazole,
and finally eluted with the same buffer supplemented with 500 mM imidazole. For DSP
crosslinking experiments, the cell pellet was washed and then resuspended in PBS buffer.
DSP was added to a final concentration of 1 mM, and the mixture was incubated at room
temperature for 30 min. To stop the reaction, a Tris-Cl buffer (pH 8.0) was added to a final
concentration of 20 mM. Cells were then pelleted, and proteins were purified similarly as
described above. To break the disulfide bond in DSP, DTT was added to the sample to a
final concentration of 10 mM.
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For Western blot analysis, after transferring to the PVDF membrane, protein bands
were detected using an Anti-AcrB polyclonal (Rabbit) antibody raised to recognize a C-
terminal peptide corresponding to residues number 1036–1045 [39] or Anti-AcrA antibody,
respectively. The membrane was then washed and incubated with an alkaline phosphatase
conjugated goat anti-rabbit secondary antibody. The BCIP/NBT (5-bromo-4-chloro-3’-
indolyphosphate and nitro-blue tetrazolium) solution was used to stain the membranes.
All experiments were repeated at least three times.
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